Axsome Therapeutics/$AXSM
1D1W1MYTD1Y5YMAX
Capital at risk
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Ticker
- $AXSM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,346
- Headquarters
- New York, United States
- Website
- www.axsome.com
AXSM Metrics
BasicAdvanced
$9.7B
-
-$3.76
0.71
-
Price and volume
Market cap
$9.7B
Beta
0.71
52-week high
$260.19
52-week low
$117.30
Average daily volume
650K
Financial strength
Current ratio
1.426
Quick ratio
1.297
Long term debt to equity
1.783
Total debt to equity
2.631
Interest coverage (TTM)
-14.20%
Profitability
EBITDA (TTM)
-172.919
Gross margin (TTM)
93.24%
Net profit margin (TTM)
-24.68%
Operating margin (TTM)
-23.55%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-16.31%
Return on equity (TTM)
-245.10%
Valuation
Price to revenue (TTM)
12.09
Price to book
115.76
Price to tangible book (TTM)
284.44
Price to free cash flow (TTM)
-130.475
Free cash flow yield (TTM)
-0.77%
Free cash flow per share (TTM)
-1.413
Growth
Revenue change (TTM)
56.87%
Earnings per share change (TTM)
-25.68%
3-year revenue growth (CAGR)
62.05%
3-year earnings per share growth (CAGR)
-4.19%
10-year earnings per share growth (CAGR)
11.29%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
Analyst projections of the future price of Axsome Therapeutics stock.
Bulls say / Bears say
Commercial momentum is strong: Q2 2026 total net product revenue increased 46% year over year to $218.4 million, led by AUVELITY growth of 51% and SUNOSI growth of 20%. (GlobeNewswire)
AUVELITY launched in June 2026 for agitation associated with dementia due to Alzheimer’s disease, adding a major new indication to Axsome’s commercial franchise and expanding the opportunity beyond major depressive disorder. (GlobeNewswire)
The pipeline offers several potential catalysts: the FDA accepted the AXS-12 NDA for narcolepsy cataplexy with a May 1, 2027 PDUFA date, while Phase 3 ADHD trials and additional AXS-05 and solriamfetol programs are advancing. (SEC)
Axsome remains loss-making despite commercial growth: it reported a $51.3 million net loss in Q2 2026 and a $115.9 million net loss for the first half, while Q2 SG&A rose to $208.1 million. (SEC)
AUVELITY represented approximately 83% of Q2 2026 product revenue, creating substantial concentration risk; weaker-than-expected uptake of the Alzheimer’s agitation indication or reimbursement pressure could materially affect results. (GlobeNewswire)
Axsome may require additional capital as it funds multiple clinical programs and commercialization efforts: it sold approximately $19.8 million of stock in the first half of 2026, while reporting that it may continue to incur substantial operating losses. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
Upcoming events
No upcoming events
AXSM News
AllArticlesVideos
Funds containing AXSM
AllUSDEURGBP
Fund name | Fund size | $AXSM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.75% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.75% |
iShares Healthcare Innovation£DRDR | £1B | 0.75% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.63% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.63% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.